NCT06961500View on ClinicalTrials.gov

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

November 1, 2030

Study Completion Date

November 1, 2030

Conditions
Follicular Lymphoma Grade 3A
Interventions
DRUG

Obinutuzumab

1000mg i.v., administered on Day 1/8/15 (D1/8/15) of Cycle 1 (C1), and D1 of C2-6

DRUG

CHOP

a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4 mg/m2 i.v., administered on D1; d) Prednisone: 100mg/d po, administered on D1-5.

DRUG

Bendamustine

90 mg/m2 i.v. drip, administered on D1-2.

Trial Locations (1)

Unknown

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER